The Daily Pulse

Health• Updated

FDA forms safety council for post-market biologic drug review

Reported by Ishita Mukherjee (Staff Writer) · The Hindu - Health ·

Source: The Hindu
Worth knowing
FDA forms safety council for post-market biologic drug reviewPhoto: Wikimedia Commons

UPDATE - follow-up to FDA sets up council for post-market review of vaccines, gene therapies: The U.S. Food and Drug Administration has set up an internal safety body within its biologics center to oversee approved products like vaccines and gene therapies after they reach the market.

Structure And Role

The new CBER Safety Council reports directly to the director of the FDA's Center for Biologics Evaluation and Research. This setup separates safety reviews from the offices that approve the products. The body replaces the older Safety Working Group and brings senior officials together to review safety signals and recommend regulatory actions.

Mandate And Scope

The council handles emerging safety concerns, potential label changes, and safety-related studies, while also advising on possible market withdrawals. Its work aims to boost accountability as treatments grow more complex. The group will also coordinate with outside groups like the Centers for Disease Control and Prevention and the National Institutes of Health, using tracking systems such as VAERS and the FDA Sentinel program.

Context

This body took effect on November 19, with more details on its structure and members coming later. Regulatory bodies often create dedicated review panels to monitor treatments more closely as they reach larger groups of patients after initial approval.

Background: This follows an earlier report, covered earlier on 20 Nov 2026: 'FDA sets up council for post-market review of vaccines, gene therapies'. Read the earlier report →

What changed since yesterday

  1. FDA forms new safety council for vaccines and gene therapies
  2. Latest

    FDA forms safety council for post-market biologic drug review

ExplainerWhy this matters

What Happened

The FDA has created the CBER Safety Council to independently review approved vaccines, gene therapies, and blood products after they enter the market.

Why It Matters

As advanced cell and gene therapies reach wider patient populations, independent post-market oversight helps regulators track rare or long-term side effects that clinical trials might not catch.

What Happens Next

The agency will release additional details on the council's structure and membership at a later date.

Read more at The Hindu - Health →